EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros
September 09, 2015 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
Combined companies’ product pipeline targets reference biologics with sales of $29 billion in 2014Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI® Capabilities...